CA2845808A1 - Dispositifs medicaux canneles d'elution de medicaments et procede de fabrication de ceux-ci - Google Patents

Dispositifs medicaux canneles d'elution de medicaments et procede de fabrication de ceux-ci Download PDF

Info

Publication number: CA2845808A1
Authority: CA; Canada
Prior art keywords: stent; groove; medical device; implantable medical; grooves
Prior art date: 2011-08-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2845808A

Other languages

English (en)

Inventor

Julio C. Palmaz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Advanced Bio Prosthetic Surfaces Ltd

Original Assignee

Advanced Bio Prosthetic Surfaces Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-19

Filing date

2012-08-16

Publication date

2013-03-28

2011-08-19 Priority claimed from US13/213,973 external-priority patent/US20120185037A1/en

2012-08-16 Application filed by Advanced Bio Prosthetic Surfaces Ltd filed Critical Advanced Bio Prosthetic Surfaces Ltd

2013-03-28 Publication of CA2845808A1 publication Critical patent/CA2845808A1/fr

Status Abandoned legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 20
229920000642 polymer Polymers 0.000 claims abstract description 35
238000000034 method Methods 0.000 claims abstract description 26
229940079593 drug Drugs 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 10
229910052751 metal Inorganic materials 0.000 claims description 37
239000002184 metal Substances 0.000 claims description 37
239000012867 bioactive agent Substances 0.000 claims description 28
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
-1 antibodies Proteins 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
108090000623 proteins and genes Proteins 0.000 claims description 4
230000003637 steroidlike Effects 0.000 claims description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
229940127219 anticoagulant drug Drugs 0.000 claims description 3
239000003963 antioxidant agent Substances 0.000 claims description 3
230000003115 biocidal effect Effects 0.000 claims description 3
230000010261 cell growth Effects 0.000 claims description 3
229940126864 fibroblast growth factor Drugs 0.000 claims description 3
238000011049 filling Methods 0.000 claims description 3
210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
102000008186 Collagen Human genes 0.000 claims description 2
108010035532 Collagen Proteins 0.000 claims description 2
102000016942 Elastin Human genes 0.000 claims description 2
108010014258 Elastin Proteins 0.000 claims description 2
102000016359 Fibronectins Human genes 0.000 claims description 2
108010067306 Fibronectins Proteins 0.000 claims description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
102000007625 Hirudins Human genes 0.000 claims description 2
108010007267 Hirudins Proteins 0.000 claims description 2
102000007547 Laminin Human genes 0.000 claims description 2
108010085895 Laminin Proteins 0.000 claims description 2
102000008072 Lymphokines Human genes 0.000 claims description 2
108010074338 Lymphokines Proteins 0.000 claims description 2
108010023197 Streptokinase Proteins 0.000 claims description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
230000000340 anti-metabolite Effects 0.000 claims description 2
230000001028 anti-proliverative effect Effects 0.000 claims description 2
229940100197 antimetabolite Drugs 0.000 claims description 2
239000002256 antimetabolite Substances 0.000 claims description 2
230000006502 antiplatelets effects Effects 0.000 claims description 2
239000003443 antiviral agent Substances 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
229940097320 beta blocking agent Drugs 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
229920001436 collagen Polymers 0.000 claims description 2
229940072645 coumadin Drugs 0.000 claims description 2
229920002549 elastin Polymers 0.000 claims description 2
239000012634 fragment Substances 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
229960002897 heparin Drugs 0.000 claims description 2
229920000669 heparin Polymers 0.000 claims description 2
239000002634 heparin fragment Substances 0.000 claims description 2
229940006607 hirudin Drugs 0.000 claims description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
102000006495 integrins Human genes 0.000 claims description 2
108010044426 integrins Proteins 0.000 claims description 2
150000002617 leukotrienes Chemical class 0.000 claims description 2
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
150000003180 prostaglandins Chemical class 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
229960005202 streptokinase Drugs 0.000 claims description 2
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 2
229960005356 urokinase Drugs 0.000 claims description 2
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 2
239000012620 biological material Substances 0.000 claims 4
230000001613 neoplastic effect Effects 0.000 claims 1
210000002889 endothelial cell Anatomy 0.000 abstract description 17
230000005012 migration Effects 0.000 abstract description 13
238000013508 migration Methods 0.000 abstract description 13
239000011248 coating agent Substances 0.000 abstract description 8
238000000576 coating method Methods 0.000 abstract description 8
239000000463 material Substances 0.000 description 27
VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 13
210000001367 artery Anatomy 0.000 description 11
238000005530 etching Methods 0.000 description 11
230000008569 process Effects 0.000 description 10
238000003490 calendering Methods 0.000 description 9
229920000052 poly(p-xylylene) Polymers 0.000 description 9
238000010276 construction Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
210000003038 endothelium Anatomy 0.000 description 7
239000010410 layer Substances 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
239000010935 stainless steel Substances 0.000 description 7
229910001220 stainless steel Inorganic materials 0.000 description 7
208000007536 Thrombosis Diseases 0.000 description 6
238000002513 implantation Methods 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
229920002120 photoresistant polymer Polymers 0.000 description 6
230000036346 tooth eruption Effects 0.000 description 6
229910000684 Cobalt-chrome Inorganic materials 0.000 description 5
239000010952 cobalt-chrome Substances 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
239000007943 implant Substances 0.000 description 5
238000003754 machining Methods 0.000 description 5
239000010409 thin film Substances 0.000 description 5
238000000151 deposition Methods 0.000 description 4
230000008021 deposition Effects 0.000 description 4
238000007373 indentation Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000001154 acute effect Effects 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229920000249 biocompatible polymer Polymers 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000009760 electrical discharge machining Methods 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000013011 mating Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000005498 polishing Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002792 vascular Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002799 BoPET Polymers 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
239000005041 Mylar™ Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
229940124558 contraceptive agent Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229910003460 diamond Inorganic materials 0.000 description 2
239000010432 diamond Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000010595 endothelial cell migration Effects 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000000608 laser ablation Methods 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000002885 thrombogenetic effect Effects 0.000 description 2
UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 2
206010061660 Artery dissection Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000003082 abrasive agent Substances 0.000 description 1
239000011358 absorbing material Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000005266 casting Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000003486 chemical etching Methods 0.000 description 1
238000005229 chemical vapour deposition Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000010408 film Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
238000010329 laser etching Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000007769 metal material Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
238000002161 passivation Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000001259 photo etching Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000007514 turning Methods 0.000 description 1
210000002073 venous valve Anatomy 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000004804 winding Methods 0.000 description 1
238000009763 wire-cut EDM Methods 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Surgery (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Media Introduction/Drainage Providing Device (AREA)
Materials For Medical Uses (AREA)

CA2845808A 2011-08-19 2012-08-16 Dispositifs medicaux canneles d'elution de medicaments et procede de fabrication de ceux-ci Abandoned CA2845808A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13/213,973		2011-08-19
US13/213,973 US20120185037A1 (en)	2000-05-19	2011-08-19	Grooved drug-eluting medical devices and method of making same
PCT/US2012/051198 WO2013043283A2 (fr)	2011-08-19	2012-08-16	Dispositifs médicaux cannelés d'élution de médicaments et procédé de fabrication de ceux-ci

Publications (1)

Publication Number	Publication Date
CA2845808A1 true CA2845808A1 (fr)	2013-03-28

Family

ID=47915068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2845808A Abandoned CA2845808A1 (fr)	2011-08-19	2012-08-16	Dispositifs medicaux canneles d'elution de medicaments et procede de fabrication de ceux-ci

Country Status (7)

Country	Link
EP (1)	EP2744530A4 (fr)
JP (1)	JP2014524314A (fr)
CN (1)	CN104053457A (fr)
AU (2)	AU2012312964A1 (fr)
CA (1)	CA2845808A1 (fr)
MX (1)	MX2014001915A (fr)
WO (1)	WO2013043283A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107049571A (zh) *	2017-05-12	2017-08-18	微创神通医疗科技（上海）有限公司	一种椎动脉支架及其制作方法
CN111904676A (zh) *	2019-05-10	2020-11-10	上海微创医疗器械（集团）有限公司	可降解载药支架及其制作方法
CN112472380B (zh) *	2019-09-12	2023-05-02	先健科技(深圳)有限公司	覆膜支架
CN112472381B (zh) *	2019-09-12	2023-06-16	先健科技(深圳)有限公司	支架
JP7255033B2 (ja) *	2020-02-26	2023-04-10	シー・アール・バード・インコーポレーテッド	放射線不透過性マーカーを有するステントグラフト及び製造方法
CN113274174B (zh) *	2021-04-30	2022-07-12	上海大学	一种自卷血管支架成形系统及成形方法
CN116350917A (zh) *	2021-12-27	2023-06-30	上海博畅医疗科技有限公司	球囊导管

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA9710342B (en) *	1996-11-25	1998-06-10	Alza Corp	Directional drug delivery stent and method of use.
JP4172912B2 (ja) *	1997-11-07	2008-10-29	エクスパンダブル・グラフツ・パートナーシツプ	脈管内ステント及び脈管内ステントの製造方法
AU2001264750B2 (en) *	2000-05-19	2006-08-31	Vactronix Scientific, Llc	Methods and apparatus for manufacturing an intravascular stent
BR0016957A (pt) *	2000-12-15	2004-06-22	Narayan Badari Nagarada Gadde	Enxerto arterial-venoso com sistema de distribuição de droga(s) e processo para o tratamento de eventos biológicos sequênciais que ocorrem em resposta à implantação de um enxerto e sistema de ministração de drogas
US7048939B2 (en) *	2001-04-20	2006-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods for the inhibition of neointima formation
US20030105512A1 (en) *	2001-12-04	2003-06-05	Nozomu Kanesaka	Stent containing medically treating material
US20050228477A1 (en) *	2004-04-09	2005-10-13	Xtent, Inc.	Topographic coatings and coating methods for medical devices
US7575593B2 (en) *	2007-01-30	2009-08-18	Medtronic Vascular, Inc.	Implantable device with reservoirs for increased drug loading
EP2303353B1 (fr) *	2008-06-12	2018-01-10	Ramot at Tel-Aviv University Ltd.	Dispositifs médicaux à élution de médicament
US8734829B2 (en) *	2009-02-13	2014-05-27	Boston Scientific Scimed, Inc.	Medical devices having polymeric nanoporous coatings for controlled therapeutic agent delivery and a nonpolymeric macroporous protective layer

2012
- 2012-08-16 CA CA2845808A patent/CA2845808A1/fr not_active Abandoned
- 2012-08-16 JP JP2014526223A patent/JP2014524314A/ja active Pending
- 2012-08-16 EP EP20120833696 patent/EP2744530A4/fr not_active Withdrawn
- 2012-08-16 AU AU2012312964A patent/AU2012312964A1/en not_active Abandoned
- 2012-08-16 MX MX2014001915A patent/MX2014001915A/es unknown
- 2012-08-16 WO PCT/US2012/051198 patent/WO2013043283A2/fr not_active Ceased
- 2012-08-16 CN CN201280049561.XA patent/CN104053457A/zh active Pending
2017
- 2017-02-20 AU AU2017201142A patent/AU2017201142A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104053457A (zh)	2014-09-17
WO2013043283A3 (fr)	2013-05-16
EP2744530A4 (fr)	2015-04-29
AU2012312964A1 (en)	2014-03-27
AU2017201142A1 (en)	2017-03-09
EP2744530A2 (fr)	2014-06-25
JP2014524314A (ja)	2014-09-22
MX2014001915A (es)	2014-05-01
WO2013043283A2 (fr)	2013-03-28

Publication	Publication Date	Title
US10758383B2 (en)	2020-09-01	Method of making recessed features on inner surface of tubular structure by photolithography
AU2017201142A1 (en)	2017-03-09	Grooved drug-eluting medical devices and method of making same
EP1983970B1 (fr)	2016-07-06	Procédés de production de dispositifs médicaux
EP1895938B1 (fr)	2019-02-20	Endoprotheses comprenant des pieds de prolongement
AU2001264750A1 (en)	2002-02-21	Methods and apparatus for manufacturing an intravascular stent
CA2834839C (fr)	2024-01-02	Surfaces implantables endoluminales et leurs procedes de fabrication
US20170135800A1 (en)	2017-05-18	Grooved drug-eluting medical devices and method of making same

Legal Events

Date	Code	Title	Description
2018-09-27	FZDE	Discontinued	Effective date: 20180816